Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
Type
[
Year
]
Filters:
Author
is
Tripepi, Giovanni
[Clear All Filters]
2023
Martino M
,
Gori M
,
Porto G
,
Pellicano M
,
Santoro L
,
Verduci C
,
Canale FAntonio
,
Loteta B
,
Moscato T
,
Alati C
, et al.
Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation.
Ann Hematol. 2023.
PubMed
Google Scholar
Martino M
,
Gori M
,
Porto G
,
Pellicano M
,
Santoro L
,
Verduci C
,
Canale FAntonio
,
Loteta B
,
Moscato T
,
Alati C
, et al.
Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
Ann Hematol. 2023.
PubMed
Google Scholar
2021
Morabito F
,
Zamagni E
,
Conticello C
,
Pavone V
,
Palmieri S
,
Bringhen S
,
Galli M
,
Mangiacavalli S
,
Derudas D
,
Rossi E
, et al.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol. 2021.
PubMed
Google Scholar
Morabito F
,
Tripepi G
,
Del Poeta G
,
Mauro FRomana
,
Reda G
,
Sportoletti P
,
Laurenti L
,
Coscia M
,
Herishanu Y
,
Varettoni M
, et al.
Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study.
Am J Hematol. 2021.
PubMed
Google Scholar
Morabito F
,
Tripepi G
,
Del Poeta G
,
Mauro FRomana
,
Reda G
,
Sportoletti P
,
Laurenti L
,
Coscia M
,
Herishanu Y
,
Bossio S
, et al.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
Am J Hematol. 2021.
PubMed
Google Scholar
Morabito F
,
Del Poeta G
,
Mauro FRomana
,
Reda G
,
Sportoletti P
,
Laurenti L
,
Coscia M
,
Herishanu Y
,
Bossio S
,
Varettoni M
, et al.
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Am J Hematol. 2021.
PubMed
Google Scholar
2019
Martino M
,
Gori M
,
Moscato T
,
Naso V
,
Ferreri A
,
Provenzano F
,
Loteta B
,
Sanguedolce MCristina
,
Console G
,
Dattola A
, et al.
The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts.
Biol Blood Marrow Transplant. 2019.
PubMed
Google Scholar